Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines

Journal of Medicinal Chemistry

Volumn 49, Issue 19, 2006, Pages 5804-5814

  Zhang, Yonghui ^a   Leon, Annette ^a   Song, Yongcheng ^a   Studer, Danielle ^a   Haase, Christa ^a   Koscielski, Lukasz A ^a   Oldfield, Eric ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYANOPHENYLBISPHOSPHONATE DERIVATIVE; ESTER; HALOGEN; NITROGEN; TERPHENYLBISPHOSPHONATE DERIVATIVE; TETRAKISPIVALOYLOXYMETHYL ESTER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN MCF 7; CELL STRAIN NCI H460; CELL STRAIN SF 268; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZENE DERIVATIVES; CELL LINE, TUMOR; DIPHOSPHONATES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISOQUINOLINES; PYRIDINES; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TERPHENYL COMPOUNDS;

EID: 33748861780     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060280e     Document Type: Article

References (37)

1. Reszka, A. A.; Rodan, G. A. Nitrogen-containing bisphosphonate mechanism of action. Mini-Rev. Med. Chem. 2004, 4, 711-719.
2. Green, J. R. Bisphosphonates: preclinical review. Oncologist 2004, 9 (Suppl. 4), 3-13.
3. Wilhelm, M.; Kunzmann, V.; Eckstein, S.; Reimer, P.; Weissinger, F.; Ruediger, T.; Tony, H. P. γδ cells for immune therapy of patients with lymphoid malignancies. Blood 2003, 102, 200-206.
4. Sanders, J. M.; Ghosh, S.; Chan, J. M.; Meints, G.; Wang, H.; Raker, A. M.; Song, Y.; Colantino, A.; Burzynska, A.; Kafarski, P.; Morita, C. T.; Oldfield, E. Quantitative structure-activity relationships for γδ T cell activation by bisphosphonates. J. Med. Chem. 2004, 47, 375-384.
5. Riebeling, C.; Forsea, A. M.; Raisova, M.; Orfanos, C. E.; Geilen, C. C. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br. J. Cancer 2002, 87 (3), 366-371.
6. Evdokiou, A.; Labrinidis, A.; Bouralexis, S.; Hay, S.; Findlay, D. M. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003, 33 (2), 216-228.
7. Iguchi, T.; Miyakawa, Y.; Yamamoto, K.; Kizaki, M.; Ikeda, Y. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell. Signalling 2003, 15, 719-727.
8. Forsea, A. M.; Muller, C.; Riebeling, C.; Orfanos, C. E.; Geilen, C. C. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br. J. Cancer 2004, 91 (4), 803-810.
9. Kitagawa, Y.; Hiraga, T.; Yura, Y.; Yoneda, T. Suppression by incadronate of invasion and growth of A-375 human melanoma in mandible in nude mice. Oncol. Rep. 2005, 13 (2), 211-216.
10. Chuah, C.; Barnes, D. J.; Kwok, M.; Corbin, A.; Deininger, M. W.; Druker, B. J.; Melo, J. V. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia 2005, 19 (11), 1896-1904.
11. Martin, M. B.; Grimley, J. S.; Lewis, J. C.; Heath, H. T., III; Bailey, B. N.; Kendrick, H.; Yardley, V.; Caldera, A.; Lira, R.; Urbina, J. A.; Moreno, S. N.; Docampo, R.; Croft, S. L.; Oldfield, E. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 2001, 44 (6), 909-916.
12. Yardley, V.; Khan, A. A.; Martin, M. B.; Slifer, T. R.; Araujo, F. G.; Moreno, S. N.; Docampo, R.; Croft, S. L.; Oldfield, E. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob. Agents Chemother. 2002, 46 (3), 929-931.
13. Martin, M. B.; Sanders, J. M.; Kendrick, H.; de Luca-Fradley, K.; Lewis, J. C.; Grimley, J. S.; Van Brussel, E. M.; Olsen, J. R.; Meints, G. A.; Burzynska, A.; Kafarski, P.; Croft, S. L.; Oldfield, E. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J. Med. Chem. 2002, 45 (14), 2904-2914.
14. Rodriguez, N.; Bailey, B. N.; Martin, M. B.; Oldfield, E.; Urbina, J. A.; Docampo, R. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J. Infect. Dis. 2002, 186 (1), 138-140.
15. Montalvetti, A.; Fernandez, A.; Sanders, J. M.; Ghosh, S.; Van Brussel, E.; Oldfield, E.; Docampo, R. Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei: in vitro RNA interference and in vivo inhibition studies. J. Biol. Chem. 2003, 278 (19), 17075-17083.
16. Ghosh, S.; Chan, J. M. W.; Lea, C. R.; Meints, G. A.; Lewis, J. C.; Tovian, Z. S.; Flessner, R. M.; Loftus, T. C.; Bruchhaus, I.; Kendrick, H.; Croft, S. L.; Kemp, R. G.; Kobayashi, S.; Nozaki, T.; Oldfield, E. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J. Med. Chem. 2004, 47 (1), 175-187.
17. Garzoni, L. R.; Caldera, A.; Meirelles, M. D. L.; de Castro, S. L.; Docampo, R.; Meints, G. A.; Oldfield, E.; Urbina, J. A. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int. J. Antimicrob. Agents 2004, 23 (3), 273-285.
18. Garzoni, L. R.; Waghabi, M. C.; Baptista, M. A.; de Castro, S. L.; Meirelles, M. D. L.; Britto, C. C.; Docampo, R.; Oldfield, E.; Urbina, J. A. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int. J. Antimicrob. Agents 2004, 23 (3), 286-290.
19. Ling, Y.; Sahota, G.; Odeh, S.; Chan, J. M.; Araujo, F. G.; Moreno, S. N.; Oldfield, E. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. J. Med. Chem. 2005, 48 (9), 3130-3140.
20. Moenkkoenen, H.; Auriola, S.; Lehenkari, P.; Kellinsalmi, M.; Hassinen, I. E.; Vepsaelaeinen, J.; Moenkkoenen, J. A new endogenous ATP analogue (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol. 2006, 147 (4), 437-445.
21. Rogers, M. J.; Brown, R. J.; Hodkin, V.; Blackburn, G. M.; Russell, R. G.; Watts, D. J. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun. 1996, 224 (3), 863-869.
22. Benford, H. L.; Frith, J. C.; Auriola, S.; Monkkonen, J.; Rogers, M. J. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharmacol. 1999, 56 (1), 131-140.
23. Hamma-Kourbali, Y.; Di Benedetto, M.; Ledoux, D.; Oudar, O.; Leroux, Y.; Lecouvey, M.; Kraemer, M. A novel non-nitrogen containing bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem. Biophys. Res. Commun. 2003, 310 (3), 816-823.
24. Lecouvey, M.; Leroux, Y.; Kraemer, M.; Crepin, M.; Manouni, D. E.; Louriki, M. Hydroxymethylene bisphosphonic acid salts and partial esters with improved bioavailability, their preparation methods and uses against cancerous tumors and other maladies. PCT Int. Appl. 2003, 66. CODEN: PIXXD2 WO 2003008425 A1 20030130.
25. Guenin, E.; Ledoux, D.; Oudar, O.; Lecouvey, M.; Kraemer, M. Structure-activity relationships of a new class of aromatic bisphosphonates that inhibit tumor cell proliferation in vitro. Anticancer Res. 2005, 25 (2A), 1139-1145.
26. Rondeau, J.-M.; Bitsch, F.; Bourgier, E.; Geiser, M.; Hemmig, R.; Kroemer, M.; Lehmann, S.; Ramage, P.; Rieffel, S.; Strauss, A.; Green, J. R.; Jahnke, W. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 2006, 1, 267-273.
27. Sanders, J. M.; Song, Y.; Chan, J. M. W.; Zhang, Y.; Jennings, S.; Kosztowski, T.; Odeh, S.; Flessner, R.; Schwerdtfeger, C.; Kotsikorou, E.; Meints, G. A.; Gómez, A. O.; González-Pacanowska, D.; Raker, A. M.; Wang, H.; Morita, C. T.; Oldfield, E. Pyridium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J. Med. Chem. 2005, 48, 2957-2963.
28. Af'erev, I. S.; Mikhalin, N. V. Reactions of vinylidenediphosphonic acid with nucleophiles. 5. Addition of heterocyclic amines and trimethylamine to vinylidenediphosphonic acid. Izv. Akad. Nauk, Ser. Khim. 1995, 8, 1590-1592.
29. Vepsalainen, J. J. Bisphosphonate prodrugs: a new synthetic strategy to tetraacyloxymethyl esters of methylenebisphosphonates. Tetrahedron Lett. 1999, 40, 8491-8493.
30. Lecouvey, M.; Mallard, I.; Bailly, T.; Burgada, R.; Leroux, Y. A mild and efficient one-pot synthesis of 1-hydroxymethylene-1,1-bisphosphonic acids. Preparation of new tripod ligands. Tetrahedron Lett. 2001, 42, 8475-8478.
31. Sanders, J. M.; Gomez, A. O.; Mao, J.; Meints, G. A.; Van Brussel, E. M.; Burzynska, A.; Kafarski, P.; Gonzalez-Pacanowska, D.; Oldfield, E. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J. Med. Chem. 2003, 46, 5171-5183.
32. Alvarez, E.; Westmore, M.; Galvin, R. J. S.; Clapp, C. L.; Considine, E. L.; Smith, S. J.; Keyes, K.; Iversen, P. W.; Delafuente, D. M.; Sulaimon, S.; Zambrano, C.; Ma, L.; Sato, M.; Martin, T. J.; Teicher, B. A.; Galbreath, E. J. Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption. Clin. Cancer Res. 2003, 9 (15), 5705-5713.
33. Saari, W. S.; Anderson, P. S. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors. U.S. Patent 5,227,506, July 13, 1993.
34. Dunford, J. E.; Thompson, K.; Coxon, F. P.; Luckman, S. P.; Hahn, F. M.; Poulter, C. D.; Ebetino, F. H.; Rogers, M. J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296 (2), 235-242.
35. Devlin, B. R. J. Biologically active compositions. Br. GB 1508772, 1978.
36. Breant, P.; Marsais, F.; Queguiner, G. Regioselective lithiation of 3-pyridylsulfonic acid derivatives: a convenient route to various new 4-substituted 3-pyridylsulfonamides. Synthesis 1983, (10), 822-824.
37. MTT cell proliferation assay. ATCC: Manassas, VA, 2001; http://www.atcc.org/documents/pdf/30-1010k.pdf.